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Abstract
Background: To update the National Malaria Control Programme of Mali on the efficacy of chloroquine,
amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria.
Methods: During the malaria transmission seasons of 2002 and 2003, 455 children – between six and 59 months
of age, with uncomplicated malaria in Kolle, Mali, were randomly assigned to one of three treatment arms. In vivo
outcomes were assessed using WHO standard protocols. Genotyping of msp1, msp2 and CA1 polymorphisms
were used to distinguish reinfection from recrudescent parasites (molecular correction).
Results: Day 28 adequate clinical and parasitological responses (ACPR) were 14.1%, 62.3% and 88.9% in 2002
and 18.2%, 60% and 85.2% in 2003 for chloroquine, amodiaquine and sulphadoxine-pyrimethamine, respectively.
After molecular correction, ACPRs (cACPR) were 63.2%, 88.5% and 98.0% in 2002 and 75.5%, 85.2% and 96.6%
in 2003 for CQ, AQ and SP, respectively. Amodiaquine was the most effective on fever. Amodiaquine therapy
selected molecular markers for chloroquine resistance, while in the sulphadoxine-pyrimethamine arm the level of
dhfr triple mutant and dhfr/dhps quadruple mutant increased from 31.5% and 3.8% in 2002 to 42.9% and 8.9% in
2003, respectively. No infection with dhps 540E was found.
Conclusion: In this study, treatment with sulphadoxine-pyrimethamine emerged as the most efficacious on
uncomplicated falciparum malaria followed by amodiaquine. The study demonstrated that sulphadoxine-
pyrimethamine and amodiaquine were appropriate partner drugs that could be associated with artemisinin
derivatives in an artemisinin-based combination therapy.
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Background
All four human malaria species Plasmodium falciparum,
Plasmodium malariae, Plasmodium ovale and  Plasmodium
vivax are present in Mali, but P. falciparum is responsible
for 86.1 to 94.9% of all malarial infections [1-3]. During
the peak transmission season, malaria is responsible for
up to 25% of mortality in children, 40% of anaemia in
pregnant women and 84% of hospital visits[3]. This
major public health problem is worsened by the steady
increase of the parasite's resistance to chloroquine (CQ),
a cheap and safe anti-malarial drug [4,5]. The magnitude
of anti-malarial drug resistance, its impact on morbidity
and mortality in endemic countries and the scarcity of
new anti-malarials have led some authors to warn for a
malaria disaster in sub-Saharan Africa [5,6]. The contin-
ued usage of a failing drug does increase the rate of
malaria mortality and morbidity, while a premature
change of anti-malarial treatment policy may lead to an
unsustainable economical burden on the health systems
of endemic countries [7]. In order to promote evidence-
based policy decisions, the World Health Organization
(WHO) stressed the need to monitor the efficacy of anti-
malarial drugs using standardized protocols [8]. This reg-
ular monitoring has led several National Malaria Control
Programmes to switch their first line treatment from CQ
to sulphadoxine-pyrimethamine (SP) or other anti-malar-
ials [9]. However, resistance to SP emerged shortly after-
wards in numerous places [10-12].
Amodiaquine (AQ) is a 4-amino quinoleine effective
against chloroquine resistant (CQR) parasites, but seldom
used because of a small risk of lethal toxicity [13]. How-
ever, a comprehensive review showed efficacy and safety
data indicating the potential of AQ in areas where CQ has
failed. Artemisinin derivatives are the most effective and
rapid acting anti-malarials known to date. To deter resist-
ance of malaria parasites to these drugs, their use is recom-
mended in combination with a second anti-malarial with
a longer half-life, a treatment regimen known as artemisi-
nin-based combination therapy (ACT). For optimum effi-
cacy of the combination, the artemisinin derivative ought
to be combined with a drug that is efficacious in the area
where it is to be used.
At the initiation of this study, the National Malaria Con-
trol Programme of Mali was in the process of formally
changing its treatment guidelines to an ACT. Updated
data on the efficacy of potential candidate monotherapies
to be used in an ACT regimen in Mali are provided.
Methods
Study design
This was an open label clinical trial conducted in Kolle,
Mali, during the malaria transmission seasons of 2002
(August 2002 – January 2003) and 2003 (July 2003 – Jan-
uary 2004). Kolle is a rural village of 2,500 people located
55 kilometers south of Bamako. Falciparum malaria is
both endemic and seasonal with parasitaemia prevalence
ranging from 40–50% in the dry season (October-May)
and 70–85% in the rainy season (June-September) [14].
Inclusion criteria for this study included: 1) parental con-
sent; 2) age between six and 59 months; 3) a positive
malaria smear; 4) an axillary temperature between 37.5°C
and 39.5°C; and 5) parasitaemia between 2,000 –
200,000 asexual parasites/μl. Exclusion criteria included:
1) haemoglobin < 5 g/dL; 2) clinical symptoms, such as
prostration, respiratory distress, renal failure, hypoglycae-
mia, shock, bleeding, severe vomiting; and 3) a history of
allergy or other severe adverse reaction to the study drugs.
Children with any of the above exclusion characteristics or
who were for any other reason determined to be too ill for
inclusion in the study, or who declined to participate in
the study, received standard and appropriate treatment,
including parenteral quinine therapy, when indicated.
Children were randomized into three treatment groups
(CQ, AQ or SP). Treatments assignment was done by sim-
ple randomization, such that patients had a 2:1:1 chance
to be assigned to the CQ, AQ and SP arms, respectively.
Standard oral CQ and AQ were administered at 25 mg/kg
over three days (10 mg/kg on days 0 and 1, 5 mg/kg on
day 2). A single dose of 25 mg/kg of sulphadoxine and
1.25 mg/kg of pyrimethamine was administered on day 0.
All subjects were observed for 60 minutes to monitor for
adverse reactions and to make sure that the medicine was
not vomited. If vomiting occurred within 30 mn, the full
dose was re-administered. If vomiting occurred after 30
mn a half dose was re-administered. All acute concomi-
tant illnesses were treated for free by the study team.
Parental written informed consent was obtained before
any protocol specific procedure was performed. The study
was approved by the ethical committee of the Faculty of
Medicine, Pharmacy and Odonto-Stomatology, Bamako,
Mali.
Data collection
Thick and thin malaria smears, venous blood, and finger
prick blood-onto-filter paper samples were collected at
the time of enrolment. Smears were Giemsa-stained. Filter
papers were air-dried and stored for genetic analysis. With
enrolment occurring on day 0, subjects were followed
actively on days 1, 2, 3, 7, 14, 21 and 28 at the clinic and
passively by 24-hour availability of a study clinician to
evaluate and treat study subjects. At all active and passive
follow-up times malaria smears and filter paper strips
were obtained and brief history and physical evaluations
made to seek signs or symptoms of persistent or recrudes-
cent malaria. When cases of in vivo resistance were identi-
fied rescue treatment with oral or parenteral quinine was
used. Cases of severe malaria in any subject evaluated at
any time, including the first three days after treatment andMalaria Journal 2009, 8:34 http://www.malariajournal.com/content/8/1/34
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whether or not they were enrolled in the study, were fully
evaluated and admitted for appropriate medical care
including parenteral quinine.
Definition of in vivo resistance
In vivo data interpretation was done using WHO protocol
for 14 and 28 days [8]. Treatment outcome were catego-
rized as adequate clinical and parasitological response at
day 14 (ACPR14) or at day 28 (ACPR28), early treatment
failure (ETF14 and ETF28), late clinical failure (LCF14
and LCF28) and late parasitological failure (LPF14 and
LPF28).
Molecular analyses
DNA extraction
DNA was extracted from dried filter paper blood samples
by the "methanol method" as described and five microlit-
ers of template were used for polymerase chain reaction
(PCR) [15].
Nested mutation specific PCR for the detection of pfcrt K76T and 
pfmdr-1 polymorphisms (CQ and AQ arms)
Nested PCR followed by restriction endonuclease diges-
tion was used to detect pfcrt K76T and pfmdr-1 polymor-
phisms, as described. Samples that failed to yield an
unequivocal result by the restriction digestion method
were re-analysed by the nested mutation specific PCR
method, as previously described[15].
Molecular detection of dhfr and dhps mutations (SP arm)
Nested mutation-specific PCR and/or restriction digestion
were performed according to published methods [16-18].
Because the dhfr mutations at codons 108, 51 and 59 [19]
and the dhps mutations at codons 437 and 540 [20] have
been suggested to be most associated with in vivo SP fail-
ure, the molecular analysis was focused on those muta-
tions. Assays for all five mutations were performed on all
in vivo resistant infections. Twice as many randomly
selected pre-treatment infections were also included in the
molecular analysis.
Molecular genotyping
DNA was obtained from day 0 and failure days samples.
Initial DNA was extracted using the "methanol
method"[15]. Samples that failed to yield interpretable
results were re-extracted using a Qiagen Kit (Valencia, CA,
USA) according to the manufacturer's instructions. Day 0
and failure days alleles of the merozoite surface proteins
msp-1, msp-2 [21,22] and the microsatellite CA1 gene loci
[23] were compared. A sample was classified as a true fail-
ure if it was recrudescent with all three markers. Cases that
could not be resolved by this genotyping method were
excluded from subsequent analyses. Molecular corrected
ACPRs for day 14 and day 28 of follow up are hereafter
designated as cACPR14 and cACPR28.
Data analysis
Based on preliminary work in Mali the failure rate of CQ
was estimated to 25%. For the comparator drugs (AQ and
SP), the failure rate was estimated to 10% for each drug.
Using an inverse sine transform approximation (Meinert,
Cochran and Cox) and assuming an alpha error of 5% and
a desired power of 90% with a desired sample size ratio of
2:1 (like double in CQ treatment group), 194 subjects in
CQ treatment group and 98 subjects in each of AQ and SP
treatment group were needed. In order to compensate for
estimated 15% of lost-to-follow-up or -compliance data, a
total of 456 subjects were expected (228 in CQ treatment
group and 114 in each of AQ and SP treatment group) to
be enrolled into the study.
Data gathered were double entered using Microsoft Access
2000 and analysed with STATA7 (stata corporation, Texas,
USA). Bartlett test, Kruskal-Wallis, Chi Pearson and Fisher
exact tests were used to compare variances, means and
correlations. In all cases the significance was set at 5%.
Results
Of the 1,831 under five years of age patients screened,
1,234 had positive smears, and 455 subjects met our
inclusion criteria (Figure 1). At baseline, the treatment
arms were comparable with regard to mean age, sex, mean
haemoglobin concentration and median parasitaemia
(Table 1).
Efficacy results
Before PCR correction rates of ACPR14 and ACPR28 were
unacceptably low for CQ (55.9% and 16.3%), moderate
to high for AQ (89.8% and 61.1) and SP (93.1% and
86.9%), respectively (Table 2). However, the majority of
the cases of failure were late clinical or parasitological fail-
ures. Only one case of ETF was observed with SP treatment
(Table 2). After molecular correction, cACPR14 and
cACPR28 remained bellow 90% for CQ and AQ but over
97% for SP (Figure 2).
A net reduction of fever was seen between Day 0 and Day
2 in each of the treatment arms. At Day 2, there was a sta-
tistically significant difference between the CQ and SP
arms for fever clearance (p < 0.05). No cases of fever were
recorded in the AQ arm at Day 2, while 17.6% of children
in the SP arm were febrile (Figure 3).
The level of anaemia in the whole population of the study
was 51.5% (N = 454) in Kollé at baseline. By day 28 there
was a non-significant decrease of anaemia prevalence to
42.9% (n = 163), 35.1% (n = 97) and 37.1% (n = 107) for
CQ, AQ and SP, respectively. The level of pruritus was
3.7%, 3.5% and 0% in the CQ, AQ and SP arms, respec-
tively.Malaria Journal 2009, 8:34 http://www.malariajournal.com/content/8/1/34
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Study profile Figure 1
Study profile.
455 patients met inclusion criteria and were randomized 
219 patients were assigned to receive 
CQ 
115 patients were assigned to receive AQ  121 patients were assigned to receive 
SP
202 patients was 
analyzable at day 14 of 
follow up
108 patients was 
analyzable at day 14 of 
follow up
116 patients was 
analyzable at day 14
8 case of pruritus
2 case of travel
2 case of convulsion
5 case of repeated vomiting
1 case of repeated vomiting 
5 case of pruritus
1 case of travel
202 patients analyzable 
at day 28 of follow up
108 patients was  
analyzable at day 28 of 
follow up
115 patients was 
analyzable at day 28
Stopped at day 14
1234 had positive smear
Screened 1831 under five years
1 case of travel
1 case of withdrawal 
because of venous blood 
taking 
2 case of polyspecific
infection at day 1
1 case of  withdrawal of consent
Table 1: Baseline characteristics of included children by treatment group
CQ AQ SP P
Mean age 3.10 (219) 2.85 (115) 2.92 (121) NS
Sex (male) 49.77% (109) 47.83% (55) 50.41% (61) NS
Fever 88.53% (193) 88.70% (102) 88.24% (105) NS
Haemoglobin 9.75 (218) 9.85 (115) 9.86 (121) NS
Median parasitaemia 30,075 (219) 24,525 (115) 24,000 (121) NS
NS = Not significantMalaria Journal 2009, 8:34 http://www.malariajournal.com/content/8/1/34
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Prevalence of molecular markers of drug resistance
At baseline, 85.0% (n = 127) of the infections carried pfcrt
76T and 49.3% (n = 136) had pfmdr-1 86Y in 2002. Pfcrt
76T and pfmdr-1 86Y were present in 64.5% (n = 172) and
35.5% (n = 169), respectively in 2003. The dhfr 108N, dhfr
triple and dhfr/dhps quadruple mutation genotype were
found in 45.5% (n = 55); 31.5% (n = 54) and 3.8% (n =
53), respectively, during the first year and 45.6% (n = 57),
42.9% (n = 56) and 8.9% (n = 56) during the second year.
No case of dhps 540E mutation was detected.
The well-known selection effect of CQ treatment on pfcrt
76T and pfmdr-1 86Y was also seen in this study. When
these markers were considered separately, treatment fail-
ure in the AQ arm was neither associated with mutations
in pfcrt (rates of pfcrt 76T were 70%,(n = 10) in the failure
group and 69% (n = 87) in the cured group; OR = 1.05,
95% CI = 0.22 – 5.60, p = 0.62) nor with pfmdr-1 (rates of
pfmdr-1 86Y level were 63.6% (n = 11) in the failure group
and 41.7% (n = 96) in the cured group, OR = 2.45, 95%
CI = 0.59 – 10.80, p = 0.14). However, when the two
ACPRs before and after molecular correction Figure 2
ACPRs before and after molecular correction. Panel A: Day 14 ACPRs; Panel B: Day 28 ACPRs.
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Table 2: Clinical and parasitological response by treatment group
ETF LCF LPF ACPR*
CQ 
%(N)
AQ 
%(N)
SP %(N) CQ 
%(N)
AQ 
%(N)
SP %(N) CQ 
%(N)
AQ 
%(N)
SP %(N) CQ 
%(N)
AQ 
%(N)
SP %(N)
14 Days 2002 5.4 (5) 0.0 (0) 0.0 (0) 7.6 (7) 0.0 (0) 0.0 (0) 38.0 
(35)
5.7 (3) 7.3 (4) 48.9 
(45)
94.3 
(50)
92.7 
(51)
2003 7.3 (8) 5.5 (3) 1.6 (1) 3.6 (4) 1.8 (1) 0.0 (0) 27.3 
(30)
7.3 (4) 4.9 (3) 61.8 
(68)
85.5 
(47)
93.4 
(57)
Total 6.4 (13) 2.8 (3) 0.9 (1) 5.4 (11) 0.9 (1) 0.0 (0) 32.2 
(65)
6.5 (7) 6.0 (7) 55.9 
(113)
89.8 
(97)
93.1 
(108)
28 Days 2002 5.4 (5) 0.0 (0) 0.0 (0) 20.7 
(19)
1.9 (1) 0.0 (0) 59.8 
(55)
35.8 
(19)
11.1 (6) 14.1 
(13)
62.3 
(33)
88.9 
(48)
2003 7.3 (8) 5.5 (3) 1.6 (1) 20.0 
(22)
5.5 (3) 0.0 (0) 54.5 
(60)
29.1 
(16)
13.1 (8) 18.2 
(20)
60.0 
(33)
85.2 
(52)
Total 6.4 (13) 2.8 (3) 0.9 (1) 20.3 
(41)
3.7 (4) 0.0 (0) 56.9 
(115)
32.4 
(35)
12.2 
(14)
16.3 
(33)
61.1 
(66)
86.9 
(100)
*RCPA day 14: CQ vs. AQ, P < 0.001; CQ vs. SP, P < 0.001; AQ vs. SP, P = 0.3; RCPA day 28: CQ vs. AQ, P < 0.001; CQ vs. SP, P < 0.001; AQ vs. 
SP, P < 0.001Malaria Journal 2009, 8:34 http://www.malariajournal.com/content/8/1/34
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mutations were considered together (pfcrt 76T and pfmdr-
1 86Y), there was a trend toward a significant association
between the presence of both mutations in an infection
and treatment failure with AQ (rate of pfcrt 76T+pfmdr-1
86Y was 60% (n = 10) in the failure group and 32.2% (n
= 87) in the cured group, OR = 3.16, 95% CI = 0.71–
14.75, p = 0.08). Furthermore, each of these mutations
was significantly selected in vivo by AQ monotherapy as
was the combination of pfcrt 76T and pfmdr-1 86Y (Figure
4).
Discussion
At the initiation of this study, the National Malaria Con-
trol Programme of Mali needed fresh data on the level of
resistance of Malian isolates of P. falciparum to CQ, AQ
and SP. These data were required in order to choose the
best partner drug to be combined with artemisinin deri-
vates. The study showed that SP was the most efficacious
drug (cACPR28 = 97.3%), followed by AQ (cACPR28 =
86.8%). The study also confirmed that CQ resistance lev-
els had reached unacceptable levels (cACPR28 = 69.8%).
Among the three treatment groups, AQ with 100% effi-
cacy by day 2 was the most effective on fever, which is a
key symptom of malaria. Because SP was largely used for
intermittent preventive treatment in pregnancy
(IPTp)[24] the Malian National Malaria Control Pro-
gramme selected AS+AQ as first-line therapy, along with
artemether-lumefantrine. These results are similar to sev-
eral published reports, that also found SP to be superior
to AQ and CQ [11,25,26].
The great majority of resistance cases found during this
study were late parasitological failure. Indeed, even in the
CQ arm where resistance was highest, only 6.4% of infec-
tions were early treatment failures. These rates are lower
than resistance rates found in other parts of Africa [27,28]
and confirm the observation that overall, anti-malarial
resistance is lower in West Africa, compared to eastern and
southern Africa [29].
Because AS/AQ is now one of the first line anti-malarial of
Mali, the potential role of CQ resistant markers as poten-
tial determinants of AQ resistance was revisited. A non sig-
nificant trend towards an association between the
simultaneous presence of pfcrt 76T + pfmdr-1 86Y and AQ
treatment failure was found. This is consistent with previ-
ous similar reports from Nigeria and Burkina Faso [30-
32]. Taken together, the available data suggests that the
combined genotype pfcrt 76T + pfmdr-1 86Y may be a use-
ful molecular marker for AQ resistance in the field. This
marker could be used as an interim tool for monitoring
the efficacy of AS/AQ in the field as new molecular mark-
ers of artemisinin resistance are investigated. Indeed, a
recent report showed that pfcrt  and  pfmdr-1  mutations
were selected in vivo by AS+AQ treatment [33].
The prevalence of the dhfr triple mutant genotype rose
from 31.5% to 42.9% and that of the dhfr/dhps quadruple
mutant genotype evolved from 3.8% to 8.9% from 2002
to 2003, respectively but these differences were not statis-
tically significant. No case of dhfr  540E mutation was
found during this study. Therefore, no quintuple muta-
tion genotype was present indicating that SP resistance
may be in its early days in this setting.
Conclusion
SP was more efficacious than AQ, which in turn was better
than CQ, for the treatment of uncomplicated falciparum
malaria in Mali. Results of this study contributed to the
change of anti-malarial treatment policy from CQ to ACT
in Mali and to the choice of AQ as a partner drug for
Fever clearance by treatment arm Figure 3
Fever clearance by treatment arm.
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Selection of molecular markers of CQ by AQ.
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artemisinin. Although SP resistance was low, the rapid
increase in the prevalence of molecular markers of SP
resistance calls for a tight surveillance of the efficacy of
this drug in the country.
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